Adagene (ADAG) Assets Average (2020 - 2026)
Adagene (ADAG) posted quarterly Assets Average of $72.4 million for Q4 2025, down 23.82% year-over-year from $95.0 million in Q4 2024, and down 7.06% quarter-over-quarter from $77.9 million in Q2 2025.
Analysis
Adagene (ADAG) Assets Average (2020 - 2026) Analysis & Trends
Adagene (ADAG) has reported Assets Average for 6 consecutive years, with $72.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets Average fell 23.82% year-over-year to $72.4 million; the TTM figure through Dec 2025 stood at $72.4 million (down 23.82% YoY), while the FY2025 annual figure was $83.8 million, down 18.28% from the prior year.
- Assets Average eased to $72.4 million in Q4 2025 per ADAG's latest filing, from $77.9 million in the prior quarter.
- Across five years, Assets Average topped out at $203.7 million in Q4 2021 and bottomed at $57.9 million in Q4 2023.
- Historically, Assets Average has averaged $101.3 million across 5 years, with a median of $86.3 million in 2022.
- Annual changes were most pronounced in 2021 — Assets Average surged 114.24% — and 2022, when it tumbled 62.59%.
- Adagene's Assets Average stood at $203.7 million in 2021, then sank by 62.59% to $76.2 million in 2022, then dropped by 24.06% to $57.9 million in 2023, then surged by 64.22% to $95.0 million in 2024, then declined by 23.82% to $72.4 million in 2025.
- Business Quant data shows ADAG's Assets Average at $72.4 million in Q4 2025, $77.9 million in Q2 2025, and $95.0 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Adagene | 211.24 Mn | 211.24 Mn | - | 105.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 105.92 Mn |
| Dec 31, 2025 | 72.39 Mn |
| Jun 30, 2025 | 77.89 Mn |
| Dec 31, 2024 | 95.02 Mn |
| Jun 30, 2024 | 108.25 Mn |
| Dec 31, 2023 | 125.52 Mn |
| Jun 30, 2023 | 143.85 Mn |
| Dec 31, 2022 | 165.48 Mn |
| Jun 30, 2022 | 184.03 Mn |
| Dec 31, 2021 | 203.69 Mn |
| Jun 30, 2021 | 151.06 Mn |
| Dec 31, 2020 | 95.08 Mn |